Penetrium Bioscience Inc
187660
Company Profile
Business description
Penetrium Bioscience Inc is engaged in CRO services and develops anticancer drugs that utilize proprietary Drug Delivery System (DDS) technology to enhance the bioavailability of active pharmaceutical ingredients (APIs) and improve selectivity for target tumor sites.
Contact
166, Magokdong-ro
Room 603
Gangseo-gu
Seoul07790
KORT: +82 27301457
Sector
Healthcare
Stock type
Defensive
Industry
Medical Care Facilities
Fiscal Year End
31 December 2026
Employees
147
Stocks News & Analysis
stocks
Major ASX miner reduces aluminium exposure
The Alcoa transaction unlocks value and sharpens ASX miners focus on base metals.
stocks
Vegemite owner’s shares remain expensive on normalising profits.
Australian dairy staple to see profits normalise with shares screening as overvalued.
stocks
Ask the analyst: Where does GYG stand following its US exit?
All roads lead back home for Guzman Y Gomez.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,028.70 | 2.90 | 0.03% |
| CAC 40 | 8,508.07 | 33.21 | 0.39% |
| DAX 40 | 25,779.31 | 198.43 | 0.78% |
| Dow JONES (US) | 52,900.07 | 594.83 | 1.14% |
| FTSE 100 | 10,679.03 | 26.16 | 0.25% |
| HKSE | 23,517.45 | 167.42 | 0.72% |
| NASDAQ | 25,832.67 | 207.36 | -0.80% |
| Nikkei 225 | 69,140.72 | 603.35 | -0.87% |
| NZX 50 Index | 13,688.72 | 70.30 | 0.52% |
| S&P 500 | 7,483.24 | 0.01 | 0.00% |
| S&P/ASX 200 | 8,824.20 | 5.90 | 0.07% |
| SSE Composite Index | 4,046.23 | 2.58 | 0.06% |